APA (7th ed.) Citation

Phillips, R. M., Loadman, P. M., & Reddy, G. (2019). Inactivation of apaziquone by haematuria: Implications for the design of phase III clinical trials against non-muscle invasive bladder cancer. Cancer chemotherapy and pharmacology, 83(6), 1183-1189. https://doi.org/10.1007/s00280-019-03812-7

Chicago Style (17th ed.) Citation

Phillips, Roger M., Paul M. Loadman, and Guru Reddy. "Inactivation of Apaziquone by Haematuria: Implications for the Design of Phase III Clinical Trials Against Non-muscle Invasive Bladder Cancer." Cancer Chemotherapy and Pharmacology 83, no. 6 (2019): 1183-1189. https://doi.org/10.1007/s00280-019-03812-7.

MLA (9th ed.) Citation

Phillips, Roger M., et al. "Inactivation of Apaziquone by Haematuria: Implications for the Design of Phase III Clinical Trials Against Non-muscle Invasive Bladder Cancer." Cancer Chemotherapy and Pharmacology, vol. 83, no. 6, 2019, pp. 1183-1189, https://doi.org/10.1007/s00280-019-03812-7.